PER-083-06已完成未知
Crash-2 Study (Clinical Randomization of an Antifibrinolytic in Significant Haemorrhage) Large Scale, Randomized, Placebo Controlled Study, on the Effects of Antifibrinolytic Treatment on Mortality and Transfusion Requirement, in Patients with Trauma who are at Risk or Present Significant Hemorrhage
ONDON SCHOOL OF HYGIENE & TROPICAL MEDICINE,0 个研究点目标入组 0 人开始时间: 2006年11月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •All patients with significant trauma and bleeding (systolic pressure less than 90 mmHg and / or heart rate greater than 110 per minute), or those who are considered to be at risk of significant bleeding and are within 8 hours are eligible for the study. of the injury if they appear to be at least 16 years old. Although patients can be admitted up to 8 hours after the injury, the sooner the patient can be treated, the better.
排除标准
- •The fundamental criterion of eligibility is the uncertainty of the responsible physician on whether or not to use an antifibrinolytic agent in a specific adult with traumatic hemorrhage. Patients in whom the responsible physician considers that there is a clear indication for the use of antifibrinolytic therapy should not be randomized. Likewise, patients in whom it is considered that there is a clear contraindication of antifibrinolytic therapy should not be randomized. All patients in whom the responsible physician is substantially undecided whether or not to use an antifibrinolytic agent are eligible for randomization. There are no other pre-specified exclusion criteria.
研究者
相似试验
进行中（未招募）
1 期
A Clinical trial to Breast Cancer where two different ways to give the chemotherapy capsules are comparedEUCTR2011-003564-72-DKAarhus University Hospital110
进行中（未招募）
1 期
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerMetastatic colorectal cancerEUCTR2005-003443-31-GBAstraZeneca AB210
进行中（未招募）
不适用
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerMetastatic colorectal cancerEUCTR2005-003443-31-CZAstraZeneca AB210
进行中（未招募）
不适用
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerEUCTR2005-003443-31-BEAstraZeneca AB210
进行中（未招募）
不适用
A Phase II, Double-blind, Randomized Study to Compare the Efficacy of AZD2171 in Combination with 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX) and the Efficacy of Bevacizumab in Combination with FOLFOX in the Second-line Treatment of Patients with Metastatic Colorectal CancerMetastatic colorectal cancerEUCTR2005-003443-31-DEAstraZeneca AB210